Apellis Pharmaceuticals, Inc. — Director's Dealing 2023

Jan 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2023-01-27

Reporting Person: Townsend Adam J. (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-27	Common Stock	F	551	$52.77	Disposed	67932	Direct

Footnotes

F1: This represents shares withheld for tax on a restricted stock unit release.